Progress of bevacizumab intraperitoneal instillation in the treatment of ovarian cancer

VernacularTitle:贝伐珠单抗腹腔灌注治疗卵巢癌的研究现状
Author: Zhi-Qi ZHANG ¹ ; Zhuo ZHANG ; Qian-Xin LIU ; Qian XIANG ; Yi-Min CUI
Author Information

1. 北京大学第一医院药学部,北京 100034
Keywords: bevacizumab; intraperitoneal perfusion; malignant tumors; rational drug use
From: The Chinese Journal of Clinical Pharmacology 2024;40(5):759-762
CountryChina
Language:Chinese
Abstract: The expression of vascular endothelial growth factor(VEGF)in ovarian cancer tissues is closely related to the degree of malignancy of ovarian cancer,and can be an effective target for ovarian cancer treatment.Bevacizumab,as a monoclonal antibody targeting VEGF,can inhibit tumor neovascularization and tumor growth,and is used for the treatment of ovarian cancer,cervical cancer,metastatic colorectal cancer and other malignant tumors.Bevacizumab administered by intraperitoneal perfusion has good efficacy for malignant ascites in tumor patients,and can alleviate patients'clinical symptoms.In recent years,more studies have explored the clinical application method,therapeutic efficacy and related adverse effects of bevacizumab intraperitoneal instillation in the treatment of ovarian cancer,and this article is a review in this field,aiming to provide reference for the clinical treatment of ovarian cancer.